About: Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves
Creator	Hägglund, Sara Ahooghalandari, Parvin Anderson, Jenna Blodörn, Krister Hu, Kefei Olofson, Ann-Sophie Poré, Lesly Pringle, John Taylor, Geraldine Vargmar, Karin Ois Valarcher, Jean-Franç
Source	Elsevier; Medline; PMC
abstract	Abstract Bovine respiratory syncytial virus (BRSV) is a major cause of bronchiolitis and pneumonia in cattle and causes yearly outbreaks with high morbidity in Europe. Commercial vaccines against this virus needs improvement of efficacy, especially in calves with BRSV-specific maternally derived antibodies (MDA). We previously reported that an experimental BRSV-ISCOM vaccine, but not a commercial vaccine, induced strong clinical and virological protection in calves with MDA, immunized at 7–15 weeks of age. The aim of the present study was to characterize the immune responses, as well as to investigate the efficacy and safety in younger animals, representing the target population for vaccination. Four groups of five 3–8 week old calves with variable levels of BRSV-specific MDA were immunized s.c. twice at a 3 weeks interval with (i) BRSV immunostimulating complexes (BRSV-ISCOMs), (ii) BRSV-protein, (iii) adjuvant, or (iv) PBS. All calves were challenged with virulent BRSV by aerosol 2 weeks later and euthanized on day 6 after infection. The cellular and humoral responses were monitored as well as the clinical signs, the viral excretion and the pathology following challenge. Despite presence of MDA at the time of the immunization, only a minimum of clinical signs were observed in the BRSV-ISCOM group after challenge. In contrast, in all control groups, clinical signs of disease were observed in most of the animals (respiratory rates up to 76min−1 and rectal temperatures up to 41°C). The clinical protection was associated to a highly significant reduction of virus replication in the upper and lower respiratory tract of calves, rapid systemic and local antibody responses and T helper cell responses dominated by IFNγ production. Animals that did not shed virus detectable by PCR or cell culture following challenge possessed particularly high levels of pulmonary IgA. The protective immunological responses to BRSV proteins and the ability to overcome the inhibiting effect of MDA were dependent on ISCOM borne antigen presentation.
has issue date	2011-11-03(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2011.07.146
bibo:pmid	21864616
has license	els-covid
sha1sum (hex)	93b2561f6153fa11b68d905215018f103aa31a17
schema:url	https://doi.org/10.1016/j.vaccine.2011.07.146
resource representing a document's title	Bovine respiratory syncytial virus ISCOMs—Immunity, protection and safety in young conventional calves
has PubMed Central identifier	PMC7115641
has PubMed identifier	21864616
schema:publication	Vaccine
resource representing a document's body	covid:93b2561f6153fa11b68d905215018f103aa31a17#body_text
is schema:about of	named entity 'vaccines' named entity 'weeks' named entity 'virus' named entity 'respiratory' named entity 'antibodies' named entity 'rectal' named entity 'age' named entity 'PCR' named entity 'vaccination' named entity 'pneumonia' covid:arg/93b2561f6153fa11b68d905215018f103aa31a17 named entity 'induced' named entity 'possessed' named entity 'responses' named entity 'high' named entity 'immune responses' named entity 'pathology' named entity 'clinical signs' named entity 'clinical' named entity 'replication' named entity 'strong' named entity 'levels' named entity 'disease' named entity 'bronchiolitis' named entity 'protein' named entity 'immune responses' named entity 'clinical signs' named entity 'virological' named entity 'PCR' named entity 'virus replication' named entity 'respiratory rates' named entity 'Bovine' named entity 'clinical signs' named entity 'adjuvant' named entity 'ISCOM' named entity 'signs of disease' named entity 'respiratory syncytial virus' named entity 'immunization' named entity 'PBS' named entity 'Bovine' named entity 'excretion' named entity 'infection' named entity 'humoral responses' named entity 'IgA' named entity 'immunostimulating' named entity 'pneumonia' named entity 'PBS' named entity 'humoral' named entity 'dependent' named entity 'responses' named entity 'yearly outbreaks' named entity 'cattle' named entity 'morbidity' named entity 'clinical signs' named entity 'lower respiratory tract' named entity 'vaccine' named entity 'virus' named entity 'Europe' named entity 'cell culture' named entity 'virulent' named entity 'antibody' named entity 'vaccines' named entity 'immunological responses' named entity 'vaccination' named entity 'antigen presentation' named entity 'pathology' named entity 'aerosol' named entity 'virus' named entity 'control groups' named entity 'antibodies' named entity 'respiratory syncytial virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software